InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD, Inc.

InspireMD is dedicated to the development of advanced technologies such as MicroNet™, which aim to transform the future of vascular procedures to improve outcomes in revascularisation.

InspireMD

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) designed for delivering neurovascular protection and stroke prevention. 
InspireMD is dedicated to the development of advanced technologies and seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes through a proprietary stent platform, CGuard™ EPS.
CGuard brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS.
InspireMD (NSPR) is traded on NASDQ Capital Markets.

Hercules Capital

Rosalind Capital Partners

Soleus Capital

Velan Capital

LifeSci Capital

Marshall Wace

Nantahala Capital Management

OrbiMed

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System (NPS).

SwitchGuard™ NPS is designed to allow the physician to reverse blood flow to the brain during a carotid artery stenting procedure, including Transcarotid Artery Revascularization (TCAR) or other neurovascular procedures. 

InspireMD expects to submit an Investigational Device Exemption (IDE) to the FDA in 2024, which, if approved, would allow the company to initiate a clinical trial to support the clearance of the SwitchGuard™ NPS coupled with CGuard Prime.

For full details click here: https://lnkd.in/dPd8z-96

#strokeprevention  #medicaladvancements #healthcareinnovation #CAS #TCAR #cguard

Just released our 2023 second round of our Fireside Chats with leading physicians sharing their perspectives and insights of the Carotid market shift toward stent first. 
Marvin Slosman | Chris Metzger | Kenneth Rosenfield | Sean Lyden | Muck Patrick| Shane Gleason
 
InspireMD continues to lead the evolution of management of Carotid disease and Stroke Prevention by way of the best-in-class therapy with the CGuard EPS stent platform.
 
A must watch, click here to watch the full 2023 Fireside Chat Series on our website and stay updated with the latest advancements: https://lnkd.in/djQFNrCA
 
Best wishes for a festive holiday season and a happy New Year filled with continuous innovation and collaboration pushing the boundaries in the Carotid Market for optimal patient outcomes!

#newbeginnings #cguard #stent #strokeprevention

InspireMD Announces Strategic Agreement with The Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions.  

The Early Feasibility Study (EFS) is expected to enroll 15 patients across three U.S. trial sites and explore the safety and feasibility of using the CGuard EPS carotid stent, with its unique MicroNet™ mesh covering, to treat acute ischemic stroke patients with tandem lesions.  

Click here for full details: https://lnkd.in/d62c6G7j

#cguard #acutecare #strokeprevention #tandem #vascularhealth #clinicaltrials

🍁 Thanksgiving Reflections 🍂
Our dedicated team at InspireMD has much to be thankful for this year. The outstanding Late Breaking C-GUARDIANS trial data, the recent CMS decision on the expansion of coverage of CAS in the USA, our successful financing, new vital senior leadership members and the undeniable growth of global awareness and recognition of our unique added value to carotid artery stenting.

Our achievements are not just milestones; they represent the collective effort and commitment to excellence that defines InspireMD and are testaments to the hard work and dedication of our incredible team. 

Looking ahead, we're excited about the opportunities the future holds. The momentum we've built is a solid foundation for the journey ahead, and we can't wait to see what we'll achieve together.

Wishing all our team, global physicians and partners a happy Thanksgiving holiday filled with joy, gratitude, and the company of loved ones.


#cguard #tcar #vascularhealth #innovationinhealthcare #strokeprevention

Grateful for the clinical guidance and support of the leading physicians in #carotid #vascularaccess. 
Thank you José Ignacio Leal Lorenzo and team for your great work in advancing vascular interventions. 

#cguard #tcar #vascularhealth #innovationinhealthcare #strokeprevention

VEITHsymposium, tomorrow morning: Exciting new developments in the treatment of carotid stenosis with mesh covered stents and TCAR will be discussed in Session 80 Friday, Nov. 17, Grand Ballroom East!
Join Us!
 
🕰️ 7:53 – 7:58
Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter
Speakers: D. Christopher Metzger, MD, Max Amor, MD
 
🕰️ 7:59 – 8:04
Update On The MicroNet-Covered Stents (C-Guard From InspireMD) For CAS: Value Overall, With High-Risk Lesions And With TCAR: Are There Any Downsides
Speakers: Musiałek Piotr, MD, DPhil, Stefan Mueller-Huelsbeck, MD
 
🕰️ 8:05 – 8:10
New Multicenter Data Showing The Long-Term Value Of The C-Guard MicroNet Mesh Covered Stent For CAS In High-Risk Carotid Lesions (Thrombotic, Calcified And Symptomatic) From The FLOW-GUARD And Other Trials
Speakers: Musiałek Piotr , MD, DPhil, Stefan Mueller-Huelsbeck, MD
 
🕰️ 8:11 – 8:16
Results From A Multicenter Italian Study Of The C-Guard Micromesh Stent For CAS: Advantages And Complications
Speakers: Francesco Speziale, MD, Gianmarco de Donato, MD, Wassim Mansour, MD, Pasqualino Sirignano, MD, Carlo Setacci, MD
 
🔍 Competitor
 
🕰️ 8:17-8:22
Real-World Results Of ~2,000 Patients Treated With The Roadsaver (Terumo) Dual-Layer Micro Mesh Carotid Stent: Advantages And Limitations
Speaker: Stefan Mueller-Huelsbeck, MD
 
Looking forward to insightful #CGuard Carotid EPS discussions on advancements in carotid stenosis treatment! 

#VEITHsymposium #MedicalAdvancements #HealthcareInnovation #CAS #TCAR

🌟 Join us tomorrow, Session 78 at VEITHsymposium in NYC.
Dr. Chris Metzger, MD and Dr. Musiałek Piotr, MD will present this important topic: Long-Term Value of The C-Guard MicroNet Mesh Covered Stent For CAS In High-Risk Carotid Lesions Versus Surgery: TCAR Pearls And Wisdom of Data.

🗓️ Date: 16.11.23
🕒 Time: 12:03-12:10
📍 Location: New York Hillton Midtown

Don't miss the chance to stay updated on the latest advancements in the field! 

#veithsymposium #medicaladvancements  #healthcareinnovation  #CAS #TCAR #cguard

This Week at VEITHsymposium: Don't Miss these Important #CGuard™ Carotid EPS Updates including long term multicenter data, the long term value of #MicroNet in high risk #carotid lesions, and the remarkable Late Breaking C-GUARDIANS #carotidarterystenting trial data demonstrating an unmatched low major adverse event rate of 0.95% through 30 days post-procedures. 

Contact us to set up a meeting with our #CGuard representatives at #VEITHsymposium: marketing@inspiremd.com
 
#strokeprevention #carotid #fdaapproval #carotidarterystenting #TCAR

Superb #PVI2023 concluded the best Paris Vascular Insights meeting to date. 
We are thankful for the great organization, the fantastic program and the lively discussions bringing together leading vascular physicians to present the latest data and innovations in the field. 
PVI’s #Carotid sessions with Europe’s top experts and the #CGuard Symposium on "CAS Today" further confirmed the value of #MicroNet and brought to light the recent Late Breaking C-GUARDIANS trial CAS data demonstrating an unmatched low major adverse event rate of 0.95% through 30 days post-procedures. 
Compliments and congratulations isabelle Van Herzeele and Eric Ducasse for their leadership roles in vascular innovation and education. Special thanks to Prof. Musiałek Piotr, Prof. Gianmarco de Donato, Dr. José Ignacio Leal Lorenzo, and Dr. Tommaso Castrucci for sharing their valuable expertise and insights.
We look forward to the future of #CarotidArteryStenting with #MicroNet embolic prevention and are ready for more exciting discussions at the upcoming VEITHsymposium this week.
Let's explore the frontier of medical progress together! 

#MedicalInnovation #InspireMDSymposium #CGuard #PVI23 #Veith23

msh id	COM:INSPIREMD
symbol	NSPR
name	InspireMD, Inc.
homepage url	https://www.inspiremd.com
country	IL
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	68
crunchbase url	-
linkedin url	-
founders	-

market cap	61.65M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	46.1
growth score 28	51.53
growth score 90	47.04
growth score 365	46.01

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.13
growth cost of revenue	0.08
growth depreciation and amortization	0.23
growth ebitda	-0.1
growth ebitda ratio	0.08
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.33
growth gross profit	0.62
growth gross profit ratio	0.35

COM:INSPIREMD

InspireMD

Last Close

2.67

21/11 21:00

Market Cap

61.65M

Beta: -

Volume Today

18.66K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	27.09M
cost of revenue	27.09M
depreciation and amortization	232K
ebitda	-20.66M
ebitda ratio	-3.33
eps	-0.82
eps diluted	-0.82
operating expenses	22.69M
operating income	-20.89M
operating income ratio	-3.37

accounts receivables	-1.21M
capital expenditure	-381K
cash at beginning of period	4.63M
cash at end of period	9.64M
inventory	2.11M
working capital ttm	42.04M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-